Cargando…
Autophagy: a new target for nonalcoholic fatty liver disease therapy
Nonalcoholic fatty liver disease (NAFLD) has gained importance in recent decades due to drastic changes in diet, especially in Western countries. NAFLD occurs as a spectrum from simple hepatic steatosis, steatohepatitis to cirrhosis, and even hepatocellular carcinoma. Although the molecular mechanis...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822806/ https://www.ncbi.nlm.nih.gov/pubmed/27099536 http://dx.doi.org/10.2147/HMER.S98120 |
_version_ | 1782425811737903104 |
---|---|
author | Mao, Yuqing Yu, Fujun Wang, Jianbo Guo, Chuanyong Fan, Xiaoming |
author_facet | Mao, Yuqing Yu, Fujun Wang, Jianbo Guo, Chuanyong Fan, Xiaoming |
author_sort | Mao, Yuqing |
collection | PubMed |
description | Nonalcoholic fatty liver disease (NAFLD) has gained importance in recent decades due to drastic changes in diet, especially in Western countries. NAFLD occurs as a spectrum from simple hepatic steatosis, steatohepatitis to cirrhosis, and even hepatocellular carcinoma. Although the molecular mechanisms underlying the development of NAFLD have been intensively investigated, many issues remain to be resolved. Autophagy is a cell survival mechanism for disposing of excess or defective organelles, and has become a hot spot for research. Recent studies have revealed that autophagy is linked to the development of NAFLD and regulation of autophagy has therapeutic potential. Autophagy reduces intracellular lipid droplets by enclosing them and fusing with lysosomes for degradation. Furthermore, autophagy is involved in attenuating inflammation and liver injury. However, autophagy is regarded as a double-edged sword, as it may also affect adipogenesis and adipocyte differentiation. Moreover, it is unclear as to whether autophagy protects the body from injury or causes diseases and even death, and the association between autophagy and NAFLD remains controversial. This review is intended to discuss, comment, and outline the progress made in this field and establish the possible molecular mechanism involved. |
format | Online Article Text |
id | pubmed-4822806 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-48228062016-04-20 Autophagy: a new target for nonalcoholic fatty liver disease therapy Mao, Yuqing Yu, Fujun Wang, Jianbo Guo, Chuanyong Fan, Xiaoming Hepat Med Review Nonalcoholic fatty liver disease (NAFLD) has gained importance in recent decades due to drastic changes in diet, especially in Western countries. NAFLD occurs as a spectrum from simple hepatic steatosis, steatohepatitis to cirrhosis, and even hepatocellular carcinoma. Although the molecular mechanisms underlying the development of NAFLD have been intensively investigated, many issues remain to be resolved. Autophagy is a cell survival mechanism for disposing of excess or defective organelles, and has become a hot spot for research. Recent studies have revealed that autophagy is linked to the development of NAFLD and regulation of autophagy has therapeutic potential. Autophagy reduces intracellular lipid droplets by enclosing them and fusing with lysosomes for degradation. Furthermore, autophagy is involved in attenuating inflammation and liver injury. However, autophagy is regarded as a double-edged sword, as it may also affect adipogenesis and adipocyte differentiation. Moreover, it is unclear as to whether autophagy protects the body from injury or causes diseases and even death, and the association between autophagy and NAFLD remains controversial. This review is intended to discuss, comment, and outline the progress made in this field and establish the possible molecular mechanism involved. Dove Medical Press 2016-03-24 /pmc/articles/PMC4822806/ /pubmed/27099536 http://dx.doi.org/10.2147/HMER.S98120 Text en © 2016 Mao et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Mao, Yuqing Yu, Fujun Wang, Jianbo Guo, Chuanyong Fan, Xiaoming Autophagy: a new target for nonalcoholic fatty liver disease therapy |
title | Autophagy: a new target for nonalcoholic fatty liver disease therapy |
title_full | Autophagy: a new target for nonalcoholic fatty liver disease therapy |
title_fullStr | Autophagy: a new target for nonalcoholic fatty liver disease therapy |
title_full_unstemmed | Autophagy: a new target for nonalcoholic fatty liver disease therapy |
title_short | Autophagy: a new target for nonalcoholic fatty liver disease therapy |
title_sort | autophagy: a new target for nonalcoholic fatty liver disease therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822806/ https://www.ncbi.nlm.nih.gov/pubmed/27099536 http://dx.doi.org/10.2147/HMER.S98120 |
work_keys_str_mv | AT maoyuqing autophagyanewtargetfornonalcoholicfattyliverdiseasetherapy AT yufujun autophagyanewtargetfornonalcoholicfattyliverdiseasetherapy AT wangjianbo autophagyanewtargetfornonalcoholicfattyliverdiseasetherapy AT guochuanyong autophagyanewtargetfornonalcoholicfattyliverdiseasetherapy AT fanxiaoming autophagyanewtargetfornonalcoholicfattyliverdiseasetherapy |